New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
07:08 EDTALIM, PSDVpSivida announces resubmission of NDA for ILUVIEN
pSivida Corp. (PSDV) announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration. In the resubmission, pSividas licensee, Alimera Sciences (ALIM), responded to questions raised in the FDAs October 2013 complete response letter and provided a safety update, which included commercial experience with ILUVIEN in Europe. Alimera is awaiting the FDAs acceptance of the resubmission and a Prescription Drug User Fee Act date. pSivida will report that information when it becomes available.
News For PSDV;ALIM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
07:02 EDTPSDVpSivida completes targeted enrollment in phase III Medidur trial
Subscribe for More Information
March 23, 2015
07:10 EDTALIMAlimera Sciences to host analyst/investor meeting
Analyst/Investor Meeting to be held in New York on March 25 at 12:15 pm. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use